Methotrexate has become the agent of choice for rheumatoid arthritis that does not respond to nonsteroidal anti-inflammatory drugs. In appropriately selected patients and with diligent monitoring, methotrexate in low weekly doses is effective and has a much better safety profile than was originally perceived.
|Number of pages
|Cleveland Clinic journal of medicine
|Published - Jan 1 1995
ASJC Scopus subject areas
- General Medicine